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1. Introduction 
Nasopharyngeal carcinoma (NPC) is a distinguishing and rare form of head and neck cancer 
whose predominant tumor type arises in the nasopharynx, the narrow tubular passage behind 
the nasal cavity. The disease is classified into three histopatholigical types by The World 
Health Organization (WHO): Keratinizing squamous cell carcinoma (SCC, WHO Type I), 
Nonkeratinizing carcinoma: differentiated (WHO Type II) and undifferentiated (WHO Type 
III) and basaloid squamous cell carcinoma1. Worldwide, there are 80,000 incident cases and 
50,000 deaths annually,2 however the disease is vastly more common in certain regions in Asia 
and Africa than anywhere else in the world. In the United States, the incidence ranges from 0.2 
and 0.5 cases per 100,000 population, which constitutes roughly 0.02% of all cancers, compared 
with endemic areas such as areas in Asia, where NPC might represent 25% of all cancers3. In 
fact, it is sometimes referred to as Cantonese cancer because it occurs in about 25 cases per 
100,000 people in this region, 25 times higher than the rest of the world4. 
Making it distinct is the fact that it differs from other head and neck squamous cell carcinomas 
(HNSCCs) in epidemiology, histology, natural history, and response to treatment. The 
remarkable geographic and demographic variation of NPC incidence suggests a multifactorial 
etiology of NPC. In endemic populations, the risk of NPC appears to be related to an 
interaction of these factors, namely Epstein-Barr virus (EBV) infection; genetic predisposition; 
and environmental factors such as the traditionally high intake of preserved foods5-7. 
2. RT and chemotherapy for locally advanced disease 
The radiosensitizing properties of systemic chemotherapy are firmly established for head 
and neck tumors8, and NPC is inherently more chemosensitive than other head and neck 
malignancies9. Therefore, it follows intuitively that adding systemic chemotherapy or 
targeted therapies to radiotherapy could provide NPC patients with additional clinical 
benefit. This hypothesis was tested in the late 1990s, and the utility of platinum-based 
chemotherapy in addition to radiation (RT) in locally advanced NPC was clearly 
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demonstrated in 1998 when the Intergroup 0099 trial was terminated prematurely due to a 
clear survival benefit in the chemotherapy with radiotherapy arm10. Since that time several 
randomized trials have been published, all varying in their chemotherapy regimens and 
timing of chemotherapy in relation to RT (Tables 1 and 2). 
 
Table 1. Randomized Trials of Chemotherapy with RT vs RT alone in locally advanced NPC 
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Table 2. OS and DFS of randomized trials of chemotherapy with RT vs. RT alone in locally 
advanced NPC 
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2.1 Neoadjuvant chemotherapy 
Four trials have assessed the role of neoadjuvant chemotherapy followed by RT versus RT 
alone. The VUMCA study11, active from 1989-1993, was a multi-center phase II trial of 339 
patients, in which 171 patients were randomized to receive neoadjuvant bleomycin, 
epirubicin, and cisplatin (BEC). The remaining 168 patients received RT alone. After a 
median followup of 49 months the authors noted increased disease free survival (DFS) in the 
chemotherapy with RT arm (52% vs 32%). However, no difference in overall survival (OS) 
was seen, and the trial was notable for an 8% rate of treatment-related death in the 
experimental arm versus 1% among patients treated with RT alone.  
A small study of 80 patients, active from 1991-1998, was published by Hareyama et al12. 
Forty patients were randomized to cisplatin and 5-fluorouracil prior to RT, and the control 
arm received RT alone. A trend toward both OS and DFS at three years was seen in the 
neoadjuvant arm (60% and 55% vs 48% and 43%, respectively), though this did not reach 
statistical significance. In 1998, Chua et al published the results of a trial active from 1989-
1993, in which 334 patients were randomized to either cisplatin and epirubicin with RT or 
RT alone13. Intention to treat analysis at three years revealed a trend toward improved DFS 
and OS in the chemoradiotherapy arm (58% and 80% vs 46% and 72%, respectively), 
however the results did not reach statistical significance.  
In 2001 Ma et al reported a trial, active from 1993-1994, in which 449 patients were 
randomized to two to three cycles of cisplatin, 5-fluorouracil, and bleomycin with RT versus 
RT alone14. Intention to treat analysis at five years revealed a statistically significant 
improvement in DFS (59% vs 49%), however, while a trend toward improved OS was noted 
this did not reach statistical significance. In 2005, Chua published an analysis of pooled data 
from the latter two trials, which together included 784 patients with a median follow up of 
67 months15. This analysis revealed a statistically significant DFS benefit in the neoadjuvant 
arm (51% vs 43%). However, consistent with the other trials, a trend toward OS (62% vs 
58%) did not reach statistical significance. In summary, four trials of neoadjuvant platinum-
based chemotherapy in addition to RT have revealed, at best, modest improvement in DFS 
and a trend toward improved overall survival. However to date no trial has shown a clear 
and statistically significant survival benefit with the neoadjuvant strategy.  
2.2 Concurrent chemotherapy 
To date, three trials have assessed the strategy of concurrent chemotherapy and RT as 
compared to RT alone. In 2002, Chan et al reported a trial, active from 1994-1997, of 350 
patients randomized to weekly low-dose cisplatin plus RT versus RT alone16. Notably, the 
study population in this trial had relatively advanced disease: 90% of patients were Ho’s stage 
III or IV, and over 70% were AJCC stage III or IV. A trend toward improved DFS at two years 
was seen (76% vs 69%), however this did not reach statistical significance. Updated data 
published in 2005 revealed modestly improved DFS and OS for the chemotherapy arm at five 
years: DFS was 60% and 52% (p = 0.06) and OS was 70% and 59% (p = 0.05) for the 
chemotherapy + RT and RT alone arms, respectively17. A subgroup analysis of this data 
revealed that patients with more advanced disease (T3 and T4) derived the most benefit. Lin et 
al reported data in 2003 from a 1993-1999 study of concurrent cisplatin and 5-fluorouracil plus 
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RT vs RT alone18. All patients in this trial had AJCC stage III or IV disease. The study revealed 
statistically significant improvement in both DFS and OS with concurrent chemotherapy: 5-
year OS rates for the chemotherapy arm were 72% compared with 54% in the control arm, and 
the 5-year DFS rates were 72 versus 53%, respectively. Of note, significantly more toxicity was 
noted in the chemotherapy arm. In 2005, Zhang et al published a trial, active from 2001-2003, 
of 115 patients randomized to six doses of weekly oxaliplatin plus concurrent RT versus RT 
alone19. Consistent with the earlier cisplatin-based trials, this study revealed a significant DFS 
and OS benefit for patients treated with concurrent platinum-based chemotherapy. For the 
chemotherapy + RT and RT alone arms, respectively, two year OS was 100% versus 77% and 
two year DFS was 96% versus 83%. In summary, three trials of concurrent platinum-based 
chemotherapy plus radiotherapy have revealed statistically significant improvements in DFS 
and OS as compared to radiotherapy alone. In these trials, the benefit was greatest in patients 
with advanced disease. 
2.3 Adjuvant chemotherapy 
The first trial that addressed the question of adding chemotherapy to RT for patients with 
NPC used an adjuvant strategy. In 1988, Rossi et al published the results of a 4 year multi-
center trial, active from 1979-1983, in which 229 patients were randomized to either adjuvant 
vincristine, cyclophosphamide, and adriamycin following RT or RT alone20. Follow up at 
four years did not reveal a statistically significant difference in DFS or OS between the two 
groups. Notably, no platinum agent was used in this trial, and therefore the lack of benefit 
must be interpreted in light of subsequent studies which have established platinum-based 
chemotherapy as the cornerstone of chemotherapy plus RT strategies in this disease. 
However, a later study of adjuvant chemotherapy, which did include cisplatin, was 
published in 2002 by Chi et al and revealed no significant DFS or OS benefit21. Between 1994 
and 1999, 157 patients were randomized to either adjuvant cisplatin with 5-fluorouriacil and 
leucovorin plus RT versuss RT alone. At five years, the DFS rates were 54.4% vs 49.5% and 
the OS rates were 60.5% and 54.5%, respectively, for the chemotherapy and RT arms. 
Neither of these differences reached statistical significance. In summary, two trials have 
addressed the strategy of adjuvant chemotherapy following RT, one of which was published 
prior to the Intergroup 0099 trial and as such did not include a platinum agent. Neither 
study revealed a statistically significant improvement in survival with adjuvant 
chemotherapy following RT as compared to RT alone.  
2.4 Neoadjuvant plus adjuvant chemotherapy 
To date, only one study has assessed the effect of combined neoadjuvant and adjuvant 
chemotherapy in addition to RT. In 1995, Chan et al reported a study of 82 patients 
randomized to two cycles of neoadjuvant and four cycles of adjuvant chemotherapy (both 
with cisplatin) plus RT vs RT alone22. No difference in either DFS or OS was noted after two 
years follow up. In summary, the single published trial of combined neoadjuvant and adjuvant 
chemotherapy (cisplatin) plus RT revealed no benefit of this strategy as compared to RT alone. 
2.5 Concurrent plus adjuvant chemotherapy 
To date, the most influential study to address the question of chemotherapy plus RT in 
locally advanced NPC utilized a combined concurrent and adjuvant platiunum-based  
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chemotherapy strategy, and, consequently, this approach has subsequently received the 
most research attention. In 1998, Al-Sarraf et al published the results of the Intergroup 0099 
study, active between 1989 and 1995, in which 193 patients were randomized to either RT 
alone or a chemotherapy arm10. Patients in the chemotherapy group were treated with 
cisplatin on days 1, 22 and 43 of the concurrent RT, and three adjuvant cycles of cisplatin 
with 5-fluorouracil were given monthly after completion of chemoradiotherapy. At 3 years, 
DFS was 69% in the chemotherapy group and 24% in the RT alone arm. Overall survival at 3 
years was 78 vs 47%, favoring chemotherapy. These results prompted early closure of the 
study, given the clear benefit demonstrated with concurrent plus adjuvant cisplatin. 
Updated analysis at 5 years confirmed the benefit of treatment, with 5-year DFS rates of 58 
vs 29% and 5-year OS rates of 67 vs 37%, both favoring the combined therapy arm23. 
Analysis of the National Cancer database since the first published results of the Intergroup 
0099 study data in 1998 has demonstrated that this study has led to a demonstrable change 
in NPC management. Of all patients enrolled in the database and matching the eligibility 
criteria of the Intergroup 0099 study, only 38% received chemotherapy along with RT prior 
to 1997, while since the publication of the data, 65% of these patients have received 
concurrent and adjuvant chemotherapy24. 
One-quarter of all patients treated on the Intergroup 0099 protocol had World Health 
Organization (WHO) stage I histology (keratinizing squamous cell carcinoma). A phase III 
randomized trial active from 1997-2003, using a similar chemotherapy and RT plan but 
restricted to patients with WHO type IIa (nonkeratinising squamous cell carcinoma) and IIb 
(undifferentiated carcinoma) histologies was published by Wee et al in 200525. The two and 
three year DFS and OS rates were statistically significant and favored the use of 
chemotherapy, confirming the findings of the Intergroup 0099 trial. Of note, the 
chemotherapy regimen used in the Wee et al study differed slightly from the Intergroup 
0099 trial in that the dose of cisplatin was given in divided doses rather than one dose, 
however, the total dose remained the same. Lee et al have published data from the Hong 
Kong NPC Study Group in which the Intergroup 0099 regimen was applied to patients with 
nonkeratinizing or undifferentiated NPC26. Preliminary results published in 2004 suggested 
a trend toward improved DFS in the chemotherapy arm. Long term follow up data 
published in 2010 confirmed the trend toward improved DFS seen on the initial analysis 
(62% vs 53% favoring chemotherapy). However, while five-year analysis showed a clear 
reduction death due to disease progression in the chemotherapy arm (28% vs 38% favoring 
chemotherapy, p = 0.08), the five-year overall survival data revealed only a modest trend 
favoring chemotherapy (68% vs 64%, p = 0.22)27. The discrepancy between a clear decreased 
in disease-associated death and nearly identical five-year overall survival was attributed to 
an increase in non-cancer deaths among patients in the chemotherapy arm.  
A similar trial, also published by Lee et al, utilized the identical chemotherapy as IG-0099, 
but assessed both the therapeutic gain with concurrent and adjuvant chemotherapy and/or 
accelerated RT28. Four arms were evaluated, conventional RT vs. accelerated fraction RT vs. 
conventional RT with concurrent and adjuvant chemotherapy vs. accelerated fraction RT 
with concurrent and adjuvant chemotherapy. After 189 patients were randomized, the study 
was closed due to poor accrual. Preliminary data after a median follow-up of 2.9 years, 
showed no statistically significant change in either OS or DFS at 3-years.  
www.intechopen.com
 
Nasopharyngeal Carcinoma: The Role for Chemotherapeutics and Targeted Agents 193 
In 2008, Chen et al published the results of a study of 316 patients performed between 2002 
and 2005, in which subjects randomized to the chemotherapy arm received weekly cisplatin 
concurrent with RT, followed by cisplatin and 5-fluorouracil every four weeks for three 
cycles following completion of RT29. Preliminary analysis after two years revealed a 
statistically significant difference in both overall (89.8% vs 79.7%) and disease free (84.6% vs 
72.5%) survival, favoring chemotherapy, at the expense of increased toxicity in the 
chemotherapy arm.  
Finally, a factorial study of four different regimens was published by Kwong et al in 200430. 
This study assessed the combination of RT alone vs three other schemas: RT with adjuvant 
chemotherapy, concurrent chemoradiotherapy and lastly, concurrent chemoradiotherapy 
followed by adjuvant chemotherapy. UFT (uracil an tegafur in a 4:1 molar ratio) was given 
concurrent with RT, while the adjuvant therapy consisted of alternating cycles of 
cisplatin/5-fluorouracil and vincristine/bleomycin/methotrexate.  
Although a trend towards improved DFS and OS was noted with the addition of concurrent 
chemotherapy, it did not reach statistical significance at 3 years. In assessing distant 
metastases rates, a significant reduction was attributable to concurrent chemotherapy. In 
this study, adjuvant chemotherapy did not improve outcome. 
3. Chemotherapy for recurrent and metastatic disease 
The management of recurrent and metastatic NPC remains challenging. Several studies 
have evaluated the use of platinum drugs in combination with various other 
chemotherapeutic agents including gemcitabine 31,32, bleomycin-5FU33, 5FU34, capecitabine35, 
bleomycin/epirubicin/5FU36, paclitaxel37, and docetaxel38. Given the known 
chemosensitivity of NPC, it is not surprising that these regimens are associated with good 
overall response rates, ranging from 56% - 79%. However, the duration of response is short, 
and median overall survival in these trials was on average approximately one year (range: 
11 – 25 mo). Two trials of non-platinum based monotherapy (gemcitabine39 and 
capecitabine40) were associated with worse overall response rates (28% and 37%, 
respectively) and similar median overall survival (7.2 and 14 months, respectively). Adding 
vinorelbine to gemcitabine for patients with platinum-resistant disease yielded an overall 
response rate of 36% with a median overall survival of 11.9 months41. Irinotecan used as 
monotherapy in heavily pretreated patients has been associated with an overall response 
rate of 14% (all partial responses) and median overall survival of 11.4 months42. The poor 
clinical outcomes associated with traditional chemotherapeutic agents underscores the 
urgent need for new and more effective therapeutic options in the locally advanced and 
metastatic setting. 
4. Targeted therapy 
Given the poor clinical outcomes associated with chemotherapeutics in the metastatic 
setting, evaluation of targeted therapies become of utmost importance (Table 3). 
Epidermal growth factor receptor (EGFR) expression in NPC has been correlated with 
decreased survival, increased rates of locoregional failure, and more aggressive disease 43,44. 
Drawing on those findings, Chan et al published a study in 2005 evaluating the anti-EGFR 
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monoclonal antibody, cetuximab, in combination with carboplatin45. This multi-center phase 
II trial enrolled 60 patients, all of who had evidence of disease progression within 12 months 
of platinum-based chemotherapy. Notably, 93.3% of patients in this trial had stage IV 
disease at the time of enrollment, and 85% had distant metastases. The treatment protocol 
consisted of carboplatin infused every three weeks for a maximum of eight cycles, along 
with cetuximab 400mg/m2 followed by 250mg/m2 weekly. The median number of 
cetuximab infusions completed was 10, with a range of 1-30. Only 53.3% of the patients 
received at least 3 carboplatin infusions. Of patients enrolled, 11.7% had a partial response 
to therapy; no complete responses were observed in this study and 48.3% of patients had 
stable disease. Median time to progression was 81 days, and median overall survival was 
233 days. Grade 3 or 4 toxicity was observed in 51.7% of patients, 31.7% of whom had 
toxicity that was attributed to cetuximab. A subsequent trial of cetuximab in combination 
with cisplatin-IMRT was reported in abstract form by Ma et al in 200846. The 20 patients in 
this trial differed from those in Chan et al in that all subjects had untreated, non-metastatic 
disease. The cetuximab dosing was the same (400mg/m2 initially, followed by 250mg/m2 
weekly). Cisplatin was administered at 30mg/m2 weekly, along with weekly IMRT. Ninety 
percent of patients received at least 5 doses of cetuximab, and 80% received at least 5 
cisplatin infusions. Preliminary analysis at 3 months revealed promising results: of 12 
patients evaluable for response, 10 had a complete response and the remaining two had 
stable disease.  
Two studies have evaluated the use of the small molecule EGFR tyrosine kinase inhibitor, 
gefitinib, as monotherapy in advanced platinum-resistant NPC. In 2008 Chua et al reported 
a single-center phase II study of 19 patients with relapsed or progressive despite at least two 
prior chemotherapy regimens (one of which included a platinum drug)47. In contrast to the 
previously mentioned trials, this study protocol assessed response to anti-EGFR therapy 
alone without any concurrent chemotherapeutic agent. Patients in the study received 
gefitinib 250mg daily until disease progression, unacceptable toxcitiy, or patient refusal. 
Median treatment duration was 10 weeks; 63% of patients were taken off study due to 
disease progression, and the remaining patients expressed a preference not to continue 
treatment. The regimen was well tolerated, with no grade 3 or 4 toxicity reported. 
Unfortunately, no patients in this study achieved either partial or complete response. 
Similar disappointing results were reported by Ma et al in 200848. In that trial, 16 patients 
with progressive disease after prior platinum-based therapy were treated with oral gefitinib 
500 mg/day. Three patients achieved stable disease (range: 2.8 – 8.5 months), and the drug 
was generally well tolerated. However, consistent with the results reported by Chua et al, 
no patient achieved a partial or complete response. In 2009, You et al presented data in 
abstract form reporting their study of the EGFR tyrosine kinase inhibitor, erlotinib49. In that 
small trial of 20 patients, subjects were first treated with up to 6 cycles of gemcitabine + a 
platinum agent (either cisplatin or carboplatin), followed by erlotinib 150 mg/day as 
maintenance (if stable disease) or 2nd line therapy (if progressive disease prior to 6 
chemotherapy cycles). Of the 11 patients evaluable for response to erlotinib, three had stable 
disease that was maintained for 3, 4, and 7 months.  
Sorafenib, a multi-kinase inhibitor with activity against VEGFR-2, VEGFR-3, PDGFR, FLT-3, 
c-kit, and the Raf isoforms c-Raf and b-Raf, was evaluated in a 2007 study published by 
Elser et al.50 Of particular theoretical interest is the anti-angiogenesis activity of sorafenib 
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mediated by its activity against the vascular endothelium growth factor receptor (VEGFR), 
given the known VEGF overexpression in NPC51-53. Notably, this study was not limited to 
NPC and also enrolled patients with SCCHN; of 27 patients enrolled, only 7 had NPC. 
Patients received sorafenib 400 mg twice daily as monotherapy, and therapy was generally 
well tolerated with few grade 3 or 4 toxicities. Although the reported response data for the 
entire patient cohort was promising (9 of 26 evaluable patients had stable disease, and one 
had a partial response), response data specific to the NPC subgroup was not separately 
reported. Median time to progression for the 7 patients with NPC was 3.2 months, and 
median overall survival was 7.7 months.  
In addition to monoclonal antibody and small molecule targeted therapy, immunotherapy 
may play a role in the future management of NPC. This approach has great theoretical 
appeal in NPC, given the strong association with Epstein-Barr virus (EBV). NPC cells 
express two distinct EBV latent membrane proteins, LMP-1 and LMP-2, and these proteins 
represent targets for adoptive immunotherapy54. In a phase I study published by Straathof 
et al in 2005, 10 patients with advanced NPC were treated with EBV-specific cytotoxic T 
lymphocytes (CTL)55. Four patients were in remission at the time of enrollment, and all 
remained disease-free 19–27 months after infusion. Of the remaining 6 patients, all with 
relapsed or refractory disease, 2 had complete responses, 1 had a partial response, 1 had 
stable disease and 2 had no response. CTL was well tolerated in this study. Follow up data 
from the same group was published in 2010, and this again demonstrated clinical benefit 
following CTL infusion56. Of 23 patients in this study (all with a history of 
relapsed/refractory NPC), 8 were in remission and 15 were not. Of the 8 patients in 
remission, 5 remained disease free at the time of publication (range: 17-75 months post-
infusion). Furthermore, CTL infusion was associated with a 48.7% overall response rate in 
patients with active disease, though for the subset of patients with metastatic disease the 
overall response rate was only 10%.  
5. Conclusion 
In summary, the anti-EGFR monoclonal antibody, cetuximab, has been associated with a 
small but significant overall response in patients with recurrent/metastatic disease who 
progressed despite platinum-based therapy. Furthermore, nearly half of the patients in that 
study achieved stable disease. Preliminary data in the locally advanced setting are more 
promising, with one small trial reporting an 83% overall response. In both of these trials, 
cetuximab was given in combination with platinum-based chemotherapy. Treatment with 
small molecule inhibitors has been less successful: two studies of the tyrosine kinase 
inhibitor, gefitinib, have shown no benefit. Inhibitors of angiogenesis are theoretically 
attractive subjects of investigation given the documented VEGF overexpression in NPC, and 
these agents warrant further investigation. Finally, the clear association between NPC and 
EBV represents a disease-specific biologic property that may be exploited via 
immunotherapy, and early work with EBV-specific cytotoxic T lymphocytes has produced 
promising results.  
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